# Sinovac Life Sciences Co., Ltd.: Phase 3 study in Pneumococcal Infectious Diseases (1125 participants)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Sinovac Life Sciences Co., Ltd. |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Lot-to-Lot Consistency Clinical Trial of PCV13 |
| NCT ID | NCT07832500 |
| Phase | Phase 3 |
| Status | not yet recruiting |
| Conditions | Pneumococcal Infectious Diseases |
| Intervention types | biological |
| Target enrollment | 1125 |
| Site countries | China |
| Posted | 2026-09-22 |
| Planned start | 2026-09 |
| Event | Newly registered study |
| Event date | 2026-09-22 |

## Why this score
- Industry sponsor (buys outsourced services).
- Phase 3: multi-site, larger budget.
- 1125 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07832500). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.